{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T12:36:53Z","timestamp":1767962213564,"version":"3.49.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.clinbiochem.2011.12.003","type":"journal-article","created":{"date-parts":[[2011,12,19]],"date-time":"2011-12-19T14:45:07Z","timestamp":1324305907000},"page":"237-242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Osteoprotegerin (OPG) and TNF-related apoptosis-inducing ligand (TRAIL) levels in malignant and benign pericardial effusions"],"prefix":"10.1016","volume":"45","author":[{"given":"Konstantinos","family":"Karatolios","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Pankuweit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Goettsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenz C.","family":"Hofbauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Timmesfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Al-Fakhri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"Maisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Schoppet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinbiochem.2011.12.003_bb0005","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jama.292.4.490","article-title":"Clinical implications of the osteoprotegerin\/RANKL\/RANK system for bone and vascular diseases","volume":"292","author":"Hofbauer","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.clinbiochem.2011.12.003_bb0010","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1161\/01.RES.0000149165.99974.12","article-title":"Regulation of vascular calcification by osteoclast regulatory factors RANKL and Osteoprotegerin","volume":"95","author":"Collin-Osdoby","year":"2004","journal-title":"Circ Res"},{"key":"10.1016\/j.clinbiochem.2011.12.003_bb0015","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1146\/annurev.immunol.24.021605.090646","article-title":"Osteoimmunology: interplay between the immune system and bone metabolism","volume":"24","author":"Walsh","year":"2006","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.clinbiochem.2011.12.003_bb0020","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1196\/annals.1443.016","article-title":"RANK\/RANKL: regulators of immune responses and bone physiology","volume":"1143","author":"Leibbrandt","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.clinbiochem.2011.12.003_bb0025","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nature04524","article-title":"Regulation of cancer cell migration and bone metastasis by RANKL","volume":"440","author":"Jones","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.clinbiochem.2011.12.003_bb0030","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1101\/gad.12.9.1260","article-title":"Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification","volume":"12","author":"Bucay","year":"1998","journal-title":"Genes Dev"},{"key":"10.1016\/j.clinbiochem.2011.12.003_bb0035","doi-asserted-by":"crossref","first-page":"31601","DOI":"10.1074\/jbc.M706078200","article-title":"Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways","volume":"282","author":"Vitovski","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinbiochem.2011.12.003_bb0040","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1158\/1078-0432.CCR-09-1692","article-title":"Death receptor agonists as a targeted therapy for cancer","volume":"16","author":"Wiezorek","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinbiochem.2011.12.003_bb0045","doi-asserted-by":"crossref","first-page":"7754","DOI":"10.1074\/jbc.M706927200","article-title":"TRAIL stimulates proliferation of vascular smooth muscle cells via activation of NF-kappaB and induction of insulin-like growth factor-1 receptor","volume":"283","author":"Kavurma","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinbiochem.2011.12.003_bb0050","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.ehj.2004.02.002","article-title":"Guidelines on the diagnosis and management of pericardial diseases executive summary; the task force on the diagnosis and management of pericardial diseases of the European society of cardiology","volume":"25","author":"Maisch","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinbiochem.2011.12.003_bb0055","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1053\/euhj.2002.3152","article-title":"Intrapericardial treatment of autoreactive pericardial effusion with triamcinolone; the way to avoid side effects of systemic corticosteroid therapy","volume":"23","author":"Maisch","year":"2002","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinbiochem.2011.12.003_bb0060","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1210\/jc.2002-020775","article-title":"Increased osteoprotegerin serum levels in men with coronary artery disease","volume":"88","author":"Schoppet","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinbiochem.2011.12.003_bb0065","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1161\/01.CIR.0000127957.43874.BB","article-title":"Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease","volume":"109","author":"Kiechl","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.clinbiochem.2011.12.003_bb0070","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1161\/01.CIR.0000031524.49139.29","article-title":"Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease","volume":"106","author":"Jono","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.clinbiochem.2011.12.003_bb0075","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.thromres.2009.11.024","article-title":"Association of serum TRAIL level with coronary artery disease","volume":"125","author":"Mori","year":"2010","journal-title":"Thromb Res"},{"key":"10.1016\/j.clinbiochem.2011.12.003_bb0080","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.atherosclerosis.2005.10.028","article-title":"Osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) levels in atherosclerosis","volume":"184","author":"Schoppet","year":"2006","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinbiochem.2011.12.003_bb0085","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1016\/S0024-3205(02)02088-X","article-title":"Locally different role of atrial natriuretic peptide (ANP) in the pericardial fluid","volume":"71","author":"So\u00f3s","year":"2002","journal-title":"Life Sci"},{"key":"10.1016\/j.clinbiochem.2011.12.003_bb0090","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/j.bbrc.2005.10.136","article-title":"TNF-related apoptosis-inducing ligand and its decoy receptor osteoprotegerin in nonischemic dilated cardiomyopathy","volume":"338","author":"Schoppet","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.clinbiochem.2011.12.003_bb0095","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.cccn.2004.02.002","article-title":"Biochemical analysis of pleural, peritoneal and pericardial effusions","volume":"343","author":"Burgess","year":"2004","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.clinbiochem.2011.12.003_bb0100","first-page":"255","article-title":"Diagnosis and management of pericardial effusions","volume":"25","author":"Ojeda","year":"2006","journal-title":"P R Health Sci J"},{"key":"10.1016\/j.clinbiochem.2011.12.003_bb0105","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1177\/172460089701200302","article-title":"The role of carcinoembryonic antigen (CEA) and neuron-specific enolase (NSE) evaluation in pericardial fluid for the recognition of malignant pericarditis","volume":"12","author":"Szturmowicz","year":"1997","journal-title":"Int J Biol Markers"},{"key":"10.1016\/j.clinbiochem.2011.12.003_bb0110","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/172460080502000107","article-title":"Diagnostic utility of CYFRA 21\u20131 and CEA assays in pericardial fluid for the recognition of neoplastic pericarditis","volume":"20","author":"Szturmowicz","year":"2005","journal-title":"Int J Biol Markers"},{"key":"10.1016\/j.clinbiochem.2011.12.003_bb0115","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1161\/01.CIR.89.6.2728","article-title":"Adenosine deaminase and carcinoembryonic antigen in pericardial effusion diagnosis, especially in suspected tuberculous pericarditis","volume":"89","author":"Koh","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.clinbiochem.2011.12.003_bb0120","first-page":"2977","article-title":"Serum osteoprotegerin levels are increased in patients with advanced prostate cancer","volume":"7","author":"Brown","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinbiochem.2011.12.003_bb0155","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood.V98.7.2269","article-title":"Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease","volume":"98","author":"Seidel","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.clinbiochem.2011.12.003_bb0130","first-page":"2306","article-title":"Serum osteoprotegerin levels in healthy controls and cancer patients","volume":"8","author":"Lipton","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinbiochem.2011.12.003_bb0135","doi-asserted-by":"crossref","first-page":"6113","DOI":"10.4049\/jimmunol.161.11.6113","article-title":"OPG\/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40","volume":"161","author":"Yun","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.clinbiochem.2011.12.003_bb0140","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1084\/jem.20051062","article-title":"TRAIL-expressing T cells induce apoptosis of vascular smooth muscle cells in the atherosclerotic plaque","volume":"203","author":"Sato","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/j.clinbiochem.2011.12.003_bb0145","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1182\/blood.V98.9.2784","article-title":"Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines","volume":"98","author":"Fiumara","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.clinbiochem.2011.12.003_bb0150","first-page":"3809","article-title":"Osteoprotegerin is expressed in colon carcinoma cells","volume":"25","author":"Pettersen","year":"2005","journal-title":"Anticancer Res"}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912011027482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912011027482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T15:37:13Z","timestamp":1757864233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009912011027482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S0009912011027482"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2011.12.003","relation":{},"ISSN":["0009-9120"],"issn-type":[{"value":"0009-9120","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Osteoprotegerin (OPG) and TNF-related apoptosis-inducing ligand (TRAIL) levels in malignant and benign pericardial effusions","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2011.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}